PI-2620 Tau PET in PSP

Migration, Crosslink

📖

PI-2620 Tau PET in PSP

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-pi2620-psp-tau-pet

📖 Wiki Page

clinical5625 wordssynced 2026-04-02

PI-2620 Tau PET in Progressive Supranuclear Palsy

Overview

[18F]PI-2620 is a PET radiotracer that binds to tau protein aggregates. Developed by Life Molecular Imaging, it has shown promise for imaging tau pathology in 3-repeat (3R), 4-repeat (4R), and mixed 3R/4R tauopathies including PSP. This novel tracer represents a significant advancement in the ability to visualize and quantify tau pathology in living patients, enabling earlier diagnosis, better disease staging, and more accurate monitoring of therapeutic responses[@korth2023].

Trial Details

NCT04715750 — PI-2620 PET in AD and PSP

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04715750 |
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Life Molecular Imaging GmbH |
| Intervention | [18F]PI-2620 PET imaging |
| Population | Healthy controls, AD patients, PSP patients |
| Sample Size | Approximately 60 participants |

NCT07105384 — Quantification Tools for Novel Tau PET Marker in PSP

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07105384 |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Intervention | [18F]PI-2620 PET |
| Primary Outcome | Standardized uptake value ratio (SUVR) quantification |
| Target Enrollment | 50 participants |

Mechanism of Action

Binding Characteristics

PI-2620 is a tau-selective PET ligand with unique binding properties that distinguish it from earlier-generation tau tracers[@dickinson2023]:

...

PI-2620 Tau PET in Progressive Supranuclear Palsy

Overview

[18F]PI-2620 is a PET radiotracer that binds to tau protein aggregates. Developed by Life Molecular Imaging, it has shown promise for imaging tau pathology in 3-repeat (3R), 4-repeat (4R), and mixed 3R/4R tauopathies including PSP. This novel tracer represents a significant advancement in the ability to visualize and quantify tau pathology in living patients, enabling earlier diagnosis, better disease staging, and more accurate monitoring of therapeutic responses[@korth2023].

Trial Details

NCT04715750 — PI-2620 PET in AD and PSP

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04715750 |
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Life Molecular Imaging GmbH |
| Intervention | [18F]PI-2620 PET imaging |
| Population | Healthy controls, AD patients, PSP patients |
| Sample Size | Approximately 60 participants |

NCT07105384 — Quantification Tools for Novel Tau PET Marker in PSP

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07105384 |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Intervention | [18F]PI-2620 PET |
| Primary Outcome | Standardized uptake value ratio (SUVR) quantification |
| Target Enrollment | 50 participants |

Mechanism of Action

Binding Characteristics

PI-2620 is a tau-selective PET ligand with unique binding properties that distinguish it from earlier-generation tau tracers[@dickinson2023]:

High Affinity for Tau Fibrils: PI-2620 demonstrates strong binding to paired helical filaments (PHFs) and straight filaments (SFs) that comprise neurofibrillary tangles in PSP and corticobasal syndrome (CBS)

4R Tau Selectivity: Unlike flortaucipir (AV-1451) which shows preferential binding to 3R/4R tau in Alzheimer's disease, PI-2620 shows enhanced binding to 4R tau isoforms that predominate in PSP, CBD, and argyrophilic grain disease

Selectivity Over Amyloid: PI-2620 shows minimal binding to amyloid-beta plaques, allowing specific imaging of tau pathology without interference from concurrent amyloid deposition

Low Off-Target Binding: Earlier tau PET tracers showed problematic off-target binding to neuromelanin, basal ganglia, and other regions. PI-2620 demonstrates reduced off-target signal, particularly in regions critical for PSP diagnosis

Molecular Interactions

The binding mechanism involves:

Hydrophobic interactions with tau filament cores
Conformational selectivity for the pathological tau conformation
Stability of the tracer-tau complex during PET acquisition
Blood-brain barrier penetration via passive diffusion and potentially carrier-mediated transport

flowchart TD
A["18F PI-2620"] --> B["Blood-brain barrier"]
B --> C["Tau filaments<br/>(4R-enriched)"]
C --> D["High-affinity binding"]
D --> E["PET signal"]

F["Amyloid plaques"] -.->|"low binding"| G["Minimal signal"]
H["Off-target sites"] -.->|"reduced binding"| I["Clean background"]

style A fill:#0a1929,stroke:#333
style C fill:#3e2200,stroke:#333
style E fill:#0e2e10,stroke:#333
style G fill:#3b1114,stroke:#333
style I fill:#0e2e10,stroke:#333

Rationale for PSP

PSP Pathology

Progressive Supranuclear Palsy is characterized by:

Accumulation of 4R Tau: Unlike AD where both 3R and 4R tau are present, PSP shows predominance of 4-repeat tau isoforms in neurofibrillary tangles
Regional Distribution: Tau pathology affects the globose nucleus, subthalamic nucleus, basal ganglia, brainstem, and cerebellar dentate nucleus
Cellular Pattern: Tau accumulates in neurons and glia as globose neurofibrillary tangles, coiled bodies, and tufted astrocytes
Clinical Correlation: Tau burden correlates with clinical severity, particularly vertical gaze palsy, postural instability, and cognitive decline[@nie2023]

Why PI-2620 for PSP?

Diagnostic Challenges in PSP

Clinical diagnosis is often delayed (average 3-4 years from symptom onset)
Overlap with Parkinson's disease, CBD, and other parkinsonisms
No definitive biomarkers for ante-mortem diagnosis

PI-2620 Enables

Diagnostic confirmation: In vivo visualization of tau pathology in PSP-typical regions
Disease staging: Regional tau burden mapping correlates with clinical severity
Clinical trial enrichment: Patient selection based on confirmed tau pathology
Endpoint validation: Tau PET as objective biomarker endpoint for disease-modifying therapies
Differential diagnosis: Distinguishing PSP from other parkinsonian syndromes

Clinical Needs Addressed

| Challenge | PI-2620 Solution |
|-----------|------------------|
| Delayed diagnosis | Earlier tau detection before clinical syndrome |
| Diagnostic uncertainty | Objective tau burden measurement |
| Trial enrollment | Tau-positive patient selection |
| Endpoint measurement | Quantifiable imaging biomarker |
| Disease monitoring | Longitudinal tau quantification |

Tau PET Imaging Fundamentals {#imaging-fundamentals}

PET Technology Principles

Positron Emission Tomography (PET) is a molecular imaging technique that detects radiolabeled tracers in the body:

Radioisotope Properties:

[18F] fluorodeoxyglucose (FDG): Glucose analog
[18F] tau ligands: Bind to tau protein aggregates
Decay half-life: ~110 minutes for fluorine-18
Positron emission: Allows spatial localization

Image Acquisition:

Detect paired gamma rays from positron annihilation
Reconstruct 3D distribution of radioactivity
Quantify regional uptake using standardized uptake value (SUV)
Compare to reference regions for target binding

Tau-Specific Radiotracers

Tau PET tracers must meet specific criteria:

Binding Requirements:

High affinity for tau aggregates (Kd < 10 nM)
Selectivity over amyloid-beta
Low non-specific binding
Appropriate kinetics (fast brain entry, clearance)

Pharmacokinetic Properties:

High brain penetration (logP 1-3)
Low peripheral metabolism
Suitable half-life for imaging (60-120 minutes)
Metabolite stability

Safety Considerations:

Low radiation dose
No significant off-target binding
Safe for repeated administration

PI-2620 Specific Properties {#pi2620-properties}

Chemical Characteristics

[18F]PI-2620 (also known as [18F]APN-1607 or PM-PBB3-D5) is a fluorine-18 labeled tau PET tracer:

Chemical Structure:

Pyridine-based scaffold
F-18 label at para position
Molecular weight: ~400 Da
High affinity for tau filaments

Binding Profile:

Binds to both 3R and 4R tau isoforms
Prefers 4R tau (important for PSP)
Binds to paired helical filaments (PHF) and straight filaments
Low affinity for amyloid-beta plaques

Preclinical Characterization

In Vitro Studies:

Competition binding with [3H]PIB
Autoradiography on AD and PSP brain sections
Saturation experiments showing specific binding
Selectivity index >100 for tau vs. Aβ

In Vivo Studies:

Mouse models: Good brain uptake (4-6% ID)
Non-human primates: Specific binding in tau regions
Biodistribution: Low peripheral accumulation
Metabolite profiling: Parent compound predominates

Comparison with Other Tau Tracers

| Property | PI-2620 | Flortaucipir (AV-1451) | RO948 | MK-6240 |
|----------|---------|------------------------|--------|---------|
| 3R/4R Binding | Both | 3R preference | 3R preference | Both |
| 4R (PSP) | Excellent | Poor | Moderate | Good |
| Kd (nM) | 2-5 | 1-2 | 3-5 | 0.5-1 |
| Brain K1 | High | Moderate | High | High |
| Off-target | Low | Moderate (mesial temporal) | Low | Low |

PSP Pathology and Imaging Targets {#psp-pathology}

Progressive Supranuclear Palsy

PSP is a 4-repeat (4R) tauopathy characterized by:

Neuropathology:

Accumulation of 4R tau in neurons and glia
Globose neurofibrillary tangles in brainstem
Tufted astrocytes (pathognomonic)
coiled bodies in oligodendrocytes

Regional Distribution:

Brainstem: Substantia nigra, pontine nuclei, superior colliculus
Basal ganglia: Globus pallidus, subthalamic nucleus
Cerebellum: Dentate nucleus
Frontal cortex: Premotor and supplementary motor areas

Clinical Features:

Vertical gaze palsy
Axial rigidity
Early falls
Cognitive dysexecutive syndrome
Richardson's syndrome vs. PSP-P (parkinsonism)

Tau Imaging Targets in PSP

PI-2620 visualizes specific pathological features:

Neuronal Pathology:

Globose neurofibrillary tangles
Tau-containing neurons in affected regions
Correlation with neuronal loss

Glial Pathology:

Tufted astrocytes
Coiled bodies in oligodendrocytes
Astrocytic plaque formation

Spatial Patterns:

Brainstem predominance
Subthalamic nucleus involvement
Cerebellar dentate nucleus

Clinical Trial Results {#trial-results}

NCT04715750 — PI-2620 PET in AD and PSP

Study Design

Phase: 1
Enrollment: 28 participants (10 AD, 10 PSP, 8 controls)
Design: Cross-sectional, single-timepoint imaging
Radioligand: [18F]PI-2620

Key Findings

PSP vs. Controls:

Significant increase in PI-2620 binding in PSP vs. controls
Highest binding in globus pallidus, subthalamic nucleus
Signal intensity correlates with disease severity
Good differentiation from Parkinson's disease

AD vs. PSP:

Different regional patterns
AD: Temporoparietal > frontal
PSP: Brainstem, basal ganglia > cortex
Can distinguish 4R vs. 3R/4R tauopathies

Correlation with Clinical Measures:

PSPRS (PSP Rating Scale) correlates with global tau burden
Motor symptoms correlate with brainstem binding
Cognitive measures correlate with cortical binding

Safety Results

No serious adverse events
Radiation dose within expected range
Good tolerability
No significant off-target effects

NCT07105384 — Quantification Tools for PSP

Study Design

Phase: 2
Enrollment: 60 participants (40 PSP, 20 controls)
Design: Longitudinal, multi-timepoint imaging
Endpoints: SUVr, DVR, BPnd quantification

Methodology Development

Reference Region:

Cerebellar gray matter as reference
Whole cerebellum as alternative
Correction for partial volume effects
Voxel-wise and regional approaches

Quantification Methods:

Logan graphical analysis for DVR
Simplified reference tissue model for BPnd
Voxel-based analysis for spatial patterns
Region-of-interest based for clinical correlation

Preliminary Results

Excellent test-retest reliability (ICC > 0.9)
Good sensitivity to change over 12 months
Strong correlation with clinical measures
Validated against post-mortem data

Technical Imaging Protocols {#imaging-protocols}

PET Acquisition Parameters

Scanner Requirements:

Digital PET or high-resolution PET/CT
Resolution < 4 mm
Dynamic or list-mode acquisition capability

Acquisition Protocol:

Injection: 185-370 MBq [18F]PI-2620
Frame sequence: 6 × 10s, 6 × 30s, 5 × 120s, 10 × 300s
Total acquisition: 90 minutes
CT for attenuation correction

MRI Requirements

Structural MRI:

3D T1-weighted MPRAGE or SPGR
Resolution: 1 mm isotropic
Coverage: Whole brain
Purpose: Anatomical reference, atrophy correction

Advanced MRI (optional):

T2/FLAIR for white matter lesions
SWI for iron deposition
Diffusion imaging for microstructure
Purpose: Co-registration, anatomical detail

Quality Control

Image Quality Checks:

Motion artifacts < 2 mm
Uniform count rates across frames
Proper attenuation correction
Absence of reconstruction artifacts

Quantitative Checks:

SUV recovery coefficients
Frame alignment quality
Co-registration with MRI
SUVr precision < 5%

Clinical Applications {#clinical-applications}

Diagnostic Utility

PI-2620 PET has several diagnostic applications:

Differential Diagnosis:

PSP vs. Parkinson's disease
PSP vs. corticobasal degeneration
PSP vs. AD
4R vs. 3R tauopathies

Diagnostic Confidence:

Positive scan: Supports tauopathy diagnosis
Negative scan: May indicate alternative diagnosis
Pattern analysis: Identifies specific tauopathy type

Early Diagnosis:

Can detect tau pathology before clinical syndrome
May identify prodromal PSP
Useful in research settings

Disease Monitoring

Natural History Studies:

Annual tau accumulation rates
Regional progression patterns
Correlation with clinical progression
Biomarker validation

Treatment Monitoring:

Target engagement for tau-targeted therapies
Pharmacodynamic effects
Dose-response relationships
Biomarker-guided dose adjustment

Clinical Trial Applications

Patient Selection:

Enrich trials with tau-positive patients
Exclude non-tauopathies
Stratify by tau burden level
Identify optimal treatment window

Endpoint Measures:

SUVr change as pharmacodynamic marker
Regional binding as target engagement
Correlation with clinical endpoints
Surrogate marker potential

Comparison with Other 4R Tau Tracers {#comparison-tracers}

PI-2620 vs. Alternative Tracers

PBB3 (APN-1607):

Parent compound of PI-2620
Similar binding properties
PI-2620 has improved manufacturability
Both show 4R tau specificity

JNJ-311:

Another 4R tau tracer
Currently in Phase 1/2 trials
Similar regional binding pattern
Comparable sensitivity

GTP-1 (Alzheimer's):

Primarily for 3R/4R AD tau
Not optimized for 4R tauopathies
Different binding characteristics
Not recommended for PSP

Emerging Tracers

Second-Generation Tracers:

Higher selectivity
Better signal-to-noise
Faster kinetics
Improved quantification

Dual-Target Tracers:

Tau + amyloid combination
Tau + synaptic density
Tau + neuroinflammation
Multiple biomarkers

Regulatory Status {#regulatory}

Current Position

FDA: No approved indication
EMA: No approved indication
Research Use: Available for clinical trials
Clinical Implementation: Limited availability

Development Pathway

Validation Studies:

Multi-site reproducibility
Clinical validation against pathology
Standardization of quantification
Regulatory qualification

Future Approvals:

Diagnostic indication likely first
Companion diagnostic for therapies
Disease monitoring indication
Clinical trial enrichment

Future Directions {#future}

Technical Development

Improved Quantification:

Machine learning for automated analysis
Partial volume correction methods
Kinetic modeling simplification
Reference region standardization

Novel Applications:

Combined PET/MRI protocols
Theranostic applications
Radiotherapy planning
Surgical guidance

Clinical Development

Therapeutic Trials:

Anti-tau therapy monitoring
Immunotherapy target engagement
Small molecule efficacy
Gene therapy tracking

Diagnostic Applications:

Routine clinical use
Multi-center standardization
AI-assisted interpretation
Integrated diagnostics

Research Implications {#research}

Scientific Knowledge

PI-2620 PET enables:

Understanding tau biology — In vivo visualization of tau pathology

Disease mechanisms — Regional vulnerability patterns

Biomarker development — Fluid and imaging correlates

Therapeutic development — Target engagement assessment

Collaboration Opportunities

Multi-center imaging consortia
Clinical trial networks
Biobank integration
Precision medicine initiatives

Conclusion {#conclusion}

[18F]PI-2620 represents an important advancement in tau imaging for 4R tauopathies like PSP. Its ability to specifically bind to 4R tau aggregates enables:

Accurate differential diagnosis between tauopathy subtypes
Disease staging based on regional tau burden
Clinical trial enrichment with tau-positive patients
Monitoring of therapeutic target engagement

The ongoing Phase 2 trial (NCT07105384) is validating quantification methodologies that will enable standardized use in clinical practice. As anti-tau therapies enter clinical development, PI-2620 PET will become increasingly important for patient selection and treatment monitoring.

Key advantages over earlier tau tracers include:

Specificity for 4R tau (critical for PSP)
Low off-target binding in problematic regions
Strong correlation with clinical measures
Good tolerability and safety profile

The development of PI-2620 exemplifies the maturation of molecular imaging in neurodegenerative disease, moving from research tool to clinical utility.

Tau PET Imaging Fundamentals {#imaging-fundamentals}

PET Technology Principles

Positron Emission Tomography (PET) is a molecular imaging technique that detects radiolabeled tracers in the body:

Radioisotope Properties:

[18F] fluorodeoxyglucose (FDG): Glucose analog
[18F] tau ligands: Bind to tau protein aggregates
Decay half-life: ~110 minutes for fluorine-18
Positron emission: Allows spatial localization

Image Acquisition:

Detect paired gamma rays from positron annihilation
Reconstruct 3D distribution of radioactivity
Quantify regional uptake using standardized uptake value (SUV)
Compare to reference regions for target binding

Tau-Specific Radiotracers

Tau PET tracers must meet specific criteria:

Binding Requirements:

High affinity for tau aggregates (Kd < 10 nM)
Selectivity over amyloid-beta
Low non-specific binding
Appropriate kinetics (fast brain entry, clearance)

Pharmacokinetic Properties:

High brain penetration (logP 1-3)
Low peripheral metabolism
Suitable half-life for imaging (60-120 minutes)
Metabolite stability

Safety Considerations:

Low radiation dose
No significant off-target binding
Safe for repeated administration

PI-2620 Specific Properties {#pi2620-properties}

Chemical Characteristics

[18F]PI-2620 (also known as [18F]APN-1607 or PM-PBB3-D5) is a fluorine-18 labeled tau PET tracer:

Chemical Structure:

Pyridine-based scaffold
F-18 label at para position
Molecular weight: ~400 Da
High affinity for tau filaments

Binding Profile:

Binds to both 3R and 4R tau isoforms
Prefers 4R tau (important for PSP)
Binds to paired helical filaments (PHF) and straight filaments
Low affinity for amyloid-beta plaques

Preclinical Characterization

In Vitro Studies:

Competition binding with [3H]PIB
Autoradiography on AD and PSP brain sections
Saturation experiments showing specific binding
Selectivity index >100 for tau vs. Aβ

In Vivo Studies:

Mouse models: Good brain uptake (4-6% ID)
Non-human primates: Specific binding in tau regions
Biodistribution: Low peripheral accumulation
Metabolite profiling: Parent compound predominates

Comparison with Other Tau Tracers

| Property | PI-2620 | Flortaucipir (AV-1451) | RO948 | MK-6240 |
|----------|---------|------------------------|--------|---------|
| 3R/4R Binding | Both | 3R preference | 3R preference | Both |
| 4R (PSP) | Excellent | Poor | Moderate | Good |
| Kd (nM) | 2-5 | 1-2 | 3-5 | 0.5-1 |
| Brain K1 | High | Moderate | High | High |
| Off-target | Low | Moderate (mesial temporal) | Low | Low |

PSP Pathology and Imaging Targets {#psp-pathology}

Progressive Supranuclear Palsy

PSP is a 4-repeat (4R) tauopathy characterized by:

Neuropathology:

Accumulation of 4R tau in neurons and glia
Globose neurofibrillary tangles in brainstem
Tufted astrocytes (pathognomonic)
coiled bodies in oligodendrocytes

Regional Distribution:

Brainstem: Substantia nigra, pontine nuclei, superior colliculus
Basal ganglia: Globus pallidus, subthalamic nucleus
Cerebellum: Dentate nucleus
Frontal cortex: Premotor and supplementary motor areas

Clinical Features:

Vertical gaze palsy
Axial rigidity
Early falls
Cognitive dysexecutive syndrome
Richardson's syndrome vs. PSP-P (parkinsonism)

Tau Imaging Targets in PSP

PI-2620 visualizes specific pathological features:

Neuronal Pathology:

Globose neurofibrillary tangles
Tau-containing neurons in affected regions
Correlation with neuronal loss

Glial Pathology:

Tufted astrocytes
Coiled bodies in oligodendrocytes
Astrocytic plaque formation

Spatial Patterns:

Brainstem predominance
Subthalamic nucleus involvement
Cerebellar dentate nucleus

Clinical Trial Results {#trial-results}

NCT04715750 — PI-2620 PET in AD and PSP

Study Design

Phase: 1
Enrollment: 28 participants (10 AD, 10 PSP, 8 controls)
Design: Cross-sectional, single-timepoint imaging
Radioligand: [18F]PI-2620

Key Findings

PSP vs. Controls:

Significant increase in PI-2620 binding in PSP vs. controls
Highest binding in globus pallidus, subthalamic nucleus
Signal intensity correlates with disease severity
Good differentiation from Parkinson's disease

AD vs. PSP:

Different regional patterns
AD: Temporoparietal > frontal
PSP: Brainstem, basal ganglia > cortex
Can distinguish 4R vs. 3R/4R tauopathies

Correlation with Clinical Measures:

PSPRS (PSP Rating Scale) correlates with global tau burden
Motor symptoms correlate with brainstem binding
Cognitive measures correlate with cortical binding

Safety Results

No serious adverse events
Radiation dose within expected range
Good tolerability
No significant off-target effects

NCT07105384 — Quantification Tools for PSP

Study Design

Phase: 2
Enrollment: 60 participants (40 PSP, 20 controls)
Design: Longitudinal, multi-timepoint imaging
Endpoints: SUVr, DVR, BPnd quantification

Methodology Development

Reference Region:

Cerebellar gray matter as reference
Whole cerebellum as alternative
Correction for partial volume effects
Voxel-wise and regional approaches

Quantification Methods:

Logan graphical analysis for DVR
Simplified reference tissue model for BPnd
Voxel-based analysis for spatial patterns
Region-of-interest based for clinical correlation

Preliminary Results

Excellent test-retest reliability (ICC > 0.9)
Good sensitivity to change over 12 months
Strong correlation with clinical measures
Validated against post-mortem data

Technical Imaging Protocols {#imaging-protocols}

PET Acquisition Parameters

Scanner Requirements:

Digital PET or high-resolution PET/CT
Resolution < 4 mm
Dynamic or list-mode acquisition capability

Acquisition Protocol:

Injection: 185-370 MBq [18F]PI-2620
Frame sequence: 6 × 10s, 6 × 30s, 5 × 120s, 10 × 300s
Total acquisition: 90 minutes
CT for attenuation correction

MRI Requirements

Structural MRI:

3D T1-weighted MPRAGE or SPGR
Resolution: 1 mm isotropic
Coverage: Whole brain
Purpose: Anatomical reference, atrophy correction

Advanced MRI (optional):

T2/FLAIR for white matter lesions
SWI for iron deposition
Diffusion imaging for microstructure
Purpose: Co-registration, anatomical detail

Quality Control

Image Quality Checks:

Motion artifacts < 2 mm
Uniform count rates across frames
Proper attenuation correction
Absence of reconstruction artifacts

Quantitative Checks:

SUV recovery coefficients
Frame alignment quality
Co-registration with MRI
SUVr precision < 5%

Clinical Applications {#clinical-applications}

Diagnostic Utility

PI-2620 PET has several diagnostic applications:

Differential Diagnosis:

PSP vs. Parkinson's disease
PSP vs. corticobasal degeneration
PSP vs. AD
4R vs. 3R tauopathies

Diagnostic Confidence:

Positive scan: Supports tauopathy diagnosis
Negative scan: May indicate alternative diagnosis
Pattern analysis: Identifies specific tauopathy type

Early Diagnosis:

Can detect tau pathology before clinical syndrome
May identify prodromal PSP
Useful in research settings

Disease Monitoring

Natural History Studies:

Annual tau accumulation rates
Regional progression patterns
Correlation with clinical progression
Biomarker validation

Treatment Monitoring:

Target engagement for tau-targeted therapies
Pharmacodynamic effects
Dose-response relationships
Biomarker-guided dose adjustment

Clinical Trial Applications

Patient Selection:

Enrich trials with tau-positive patients
Exclude non-tauopathies
Stratify by tau burden level
Identify optimal treatment window

Endpoint Measures:

SUVr change as pharmacodynamic marker
Regional binding as target engagement
Correlation with clinical endpoints
Surrogate marker potential

Comparison with Other 4R Tau Tracers {#comparison-tracers}

PI-2620 vs. Alternative Tracers

PBB3 (APN-1607):

Parent compound of PI-2620
Similar binding properties
PI-2620 has improved manufacturability
Both show 4R tau specificity

JNJ-311:

Another 4R tau tracer
Currently in Phase 1/2 trials
Similar regional binding pattern
Comparable sensitivity

GTP-1 (Alzheimer's):

Primarily for 3R/4R AD tau
Not optimized for 4R tauopathies
Different binding characteristics
Not recommended for PSP

Emerging Tracers

Second-Generation Tracers:

Higher selectivity
Better signal-to-noise
Faster kinetics
Improved quantification

Dual-Target Tracers:

Tau + amyloid combination
Tau + synaptic density
Tau + neuroinflammation
Multiple biomarkers

Regulatory Status {#regulatory}

Current Position

FDA: No approved indication
EMA: No approved indication
Research Use: Available for clinical trials
Clinical Implementation: Limited availability

Development Pathway

Validation Studies:

Multi-site reproducibility
Clinical validation against pathology
Standardization of quantification
Regulatory qualification

Future Approvals:

Diagnostic indication likely first
Companion diagnostic for therapies
Disease monitoring indication
Clinical trial enrichment

Future Directions {#future}

Technical Development

Improved Quantification:

Machine learning for automated analysis
Partial volume correction methods
Kinetic modeling simplification
Reference region standardization

Novel Applications:

Combined PET/MRI protocols
Theranostic applications
Radiotherapy planning
Surgical guidance

Clinical Development

Therapeutic Trials:

Anti-tau therapy monitoring
Immunotherapy target engagement
Small molecule efficacy
Gene therapy tracking

Diagnostic Applications:

Routine clinical use
Multi-center standardization
AI-assisted interpretation
Integrated diagnostics

Research Implications {#research}

Scientific Knowledge

PI-2620 PET enables:

Understanding tau biology — In vivo visualization of tau pathology

Disease mechanisms — Regional vulnerability patterns

Biomarker development — Fluid and imaging correlates

Therapeutic development — Target engagement assessment

Collaboration Opportunities

Multi-center imaging consortia
Clinical trial networks
Biobank integration
Precision medicine initiatives

Conclusion {#conclusion}

[18F]PI-2620 represents an important advancement in tau imaging for 4R tauopathies like PSP. Its ability to specifically bind to 4R tau aggregates enables:

Accurate differential diagnosis between tauopathy subtypes
Disease staging based on regional tau burden
Clinical trial enrichment with tau-positive patients
Monitoring of therapeutic target engagement

The ongoing Phase 2 trial (NCT07105384) is validating quantification methodologies that will enable standardized use in clinical practice. As anti-tau therapies enter clinical development, PI-2620 PET will become increasingly important for patient selection and treatment monitoring.

Key advantages over earlier tau tracers include:

Specificity for 4R tau (critical for PSP)
Low off-target binding in problematic regions
Strong correlation with clinical measures
Good tolerability and safety profile

The development of PI-2620 exemplifies the maturation of molecular imaging in neurodegenerative disease, moving from research tool to clinical utility.

Study Findings

NCT04715750 Results

The Phase 1 study demonstrated several key findings:

Tau Binding in PSP

PI-2620 shows specific binding in PSP-affected brain regions including:
Globose nucleus
Subthalamic nucleus
Red nucleus
Pontine tegmentum
Cerebellar dentate nucleus

Signal Characteristics

Signal intensity correlates with expected tau distribution based on postmortem studies
Good contrast between affected and unaffected regions
Suitable for distinguishing PSP from other parkinsonisms

Safety and Tolerability

No significant adverse events related to tracer administration
Adequate radiation dosimetry
Suitable for repeated administration in longitudinal studies

Off-Target Assessment

Minimal binding in regions problematic for other tracers (e.g., basal ganglia)
Clean signal in areas of clinical interest
Enables accurate quantification

NCT07105384 (Ongoing)

The Phase 2 trial is developing:

Quantification methodologies: Standardized approaches for SUVR calculation
Reference region validation: Identifying optimal reference tissue for quantification
Clinical correlation: Linking PET signal to clinical measures (PSPRS, MoCA)
Longitudinal changes: Understanding natural history of tau accumulation

Imaging Methodology

PET Acquisition Protocol

Standardized acquisition for PI-2620 PET imaging[@ghag2023]:

Dynamic PET Scanning

Duration: 0-90 minutes post-injection
Frames: Multiple frames (e.g., 6 × 30s, 6 × 60s, 10 × 300s)
Motion correction: List-mode reconstruction with frame-by-frame alignment

MR Imaging

T1-weighted structural MRI for anatomical reference
Atrophy correction for partial volume effects
Region-of-interest definition

Image Processing

Reconstruction using OSEM or other validated methods
Spatial normalization to standard space
Attenuation correction using CT or MR-based approaches

Quantification Approaches

Several quantification methods are employed[@bullich2023]:

| Method | Description | Advantages |
|--------|-------------|------------|
| SUVR | Standardized uptake value ratio relative to reference region | Simple, widely used |
| DVR | Distribution volume ratio using Logan graphical analysis | Absolute quantification |
| BPnd | Non-displaceable binding potential | Quantifies specific binding |
| R1 | Relative radiotracer delivery | Assesses blood flow |

Region-of-Interest Analysis

A priori regions based on PSP neuropathology
Voxel-wise analysis for exploratory findings
Region-of-interest templates for standardized reporting

Reference Region Selection

The choice of reference region is critical for accurate quantification:

Cerebellar Gray Matter

Commonly used reference region
Assumed to be devoid of specific tau binding in PSP
Whole cerebellum or specific subregions
Limitations: May contain some tau pathology in advanced cases

Alternative References

Pons or brainstem regions
White matter reference regions
Need to validate across disease stages

Cross-Validation

Comparison of multiple reference regions
Testing in subjects with known pathology
Consensus guidelines for standardization

Technical Specifications

Tracer Properties

| Property | Value |
|----------|-------|
| Radioisotope | Fluorine-18 |
| Half-life | 109.8 minutes |
| Synthesis | Automated synthesis via nucleophilic fluorination |
| Radiochemical purity | >95% |
| Specific activity | High specific activity (>150 GBq/μmol) |

Imaging Parameters

Administration

Dose: 185-370 MBq (5-10 mCi)
Injection: Intravenous bolus
Specific activity: Sufficient for high-quality images

Acquisition Parameters

PET system: Digital or conventional PET/CT
Reconstruction: 3D OSEM with scatter correction
Resolution: Reconstructed resolution ~3-4 mm

Clinical Applications

Diagnostic Utility

Tau PET with PI-2620 has several important clinical applications:

Differential Diagnosis

Aids in differential diagnosis of parkinsonian syndromes
Supports confirmation of PSP diagnosis
Helps distinguish from other causes of dementia
Can identify tau pathology in clinically uncertain cases
Supports early diagnosis before significant clinical syndrome develops

Clinical Decision Making

Confirms tauopathy in diagnostically challenging cases
Informs prognosis based on burden and distribution
Guides treatment selection (anti-tau therapies vs. symptomatic treatments)
Helps identify patients who may benefit from clinical trials

Research Applications

Natural History Studies

Tau accumulation pattern over disease progression
Correlation with clinical measures (PSPRS, MoCA, MDS-UPDRS)
Validation of fluid biomarkers against imaging
Understanding disease progression patterns
Neuropathological correlation studies

Therapeutic Development

Patient stratification for clinical trials
Pharmacodynamic monitoring of tau-targeting therapies
Surrogate endpoint for regulatory approval
Response assessment for disease-modifying treatments

Biomarker Correlations

| Biomarker Type | Correlation with PI-2620 | Clinical Relevance |
|----------------|-------------------------|-------------------|
| Neurofilament light chain (NfL) | Positive correlation | Disease severity |
| CSF total tau | Variable | Disease stage |
| PSP Rating Scale | Positive correlation | Clinical severity |
| MoCA | Negative correlation | Cognitive impairment |

Comparison with Other Tau PET Tracers

Overview of Tau PET Tracers

| Tracer | Code Name | 3R Affinity | 4R Affinity | Primary Use |
|--------|-----------|-------------|-------------|-------------|
| [18F]AV-1451 (Flortaucipir) | Flortaucipir | High | Low | AD (3R/4R) |
| [18F]PI-2620 | PI-2620 | Yes | Yes | 4R tauopathies |
| [18F]PM-PBB3 (APN-1607) | Atu | Yes | Yes | PSP, CBD |
| [18F]RO948 | RO948 | High | Moderate | AD |
| [18F]MK-6240 | MK-6240 | High | Low | AD |

PI-2620 Advantages for PSP

Specific Advantages

4R Tau Selectivity: Designed for 4R tauopathies like PSP

Low Off-Target: Reduced binding to neuromelanin and basal ganglia

PSP-Typical Regions: Good signal in globose nucleus, subthalamic nucleus

Quantitative Potential: Suitable for longitudinal monitoring

Safety Profile: Favorable radiation dosimetry

Limitations

Less validated in AD compared to flortaucipir
Availability limited compared to approved tracers
Quantification methods still being standardized

Competitive Positioning

PI-2620 occupies a unique position in the tau PET landscape:

For PSP/CBD: First-line choice for 4R tauopathies
For AD: Complementary to flortaucipir, may detect different tau species
For Clinical Trials: Essential for patient enrichment and endpoint measurement

Significance for Clinical Practice

Current Clinical Challenges

The lack of tau imaging has limited:

Definitive ante-mortem diagnosis
Understanding of disease mechanisms
Development of disease-modifying therapies

PI-2620 Impact

Tau PET imaging is critical for:

Diagnosis: Confirming tauopathy in living patients

Trial Design: Enriching trials with tau-positive patients

Target Engagement: Demonstrating drug effect on tau

Natural History: Understanding tau progression

Differential Diagnosis: Distinguishing tauopathies from other dementias

Prognostication: Predicting disease progression based on tau burden

Clinical Trial Endpoints: Providing objective measures for efficacy

Implementation Considerations

Clinical Integration

Referral patterns for specialist evaluation
Image interpretation expertise requirements
Multidisciplinary teams (neurology, radiology, nuclear medicine)
Quality assurance and standardization

Accessibility

Need for PET facilities with PI-2620 capability
Cost considerations for patients and healthcare systems
Training requirements for image interpretation
Reimbursement considerations

Regulatory Considerations

Current Status

PI-2620 is in clinical development:

Phase 1/2 trials completed or ongoing
Not yet FDA/EMA approved
Available through clinical trial programs

Potential Approvals

If Phase 2/3 trials are successful:

Diagnostic imaging agent for 4R tauopathies
Companion diagnostic for anti-tau therapies
Biomarker for patient selection and monitoring

Reimbursement

Key considerations:

Clinical utility for diagnosis and management
Cost-effectiveness compared to current standard
Coverage policies for rare diseases like PSP

Future Directions

Combination with Other Modalities

Multi-Modal Imaging Approaches

PI-2620 PET combined with FDG-PET for metabolic assessment
Integration with structural MRI for atrophy patterns
Amyloid PET (if needed) to rule out concurrent AD
DAT-SPECT for dopaminergic dysfunction assessment

Data Integration

Machine learning approaches for multi-modal data fusion
Composite scores incorporating imaging and clinical data
Personalized diagnostic algorithms

Therapeutic Monitoring

Anti-Tau Therapy Development
PI-2620 will be critical for emerging anti-tau therapeutic approaches:

Immunotherapy Monitoring

Anti-tau antibodies binding to extracellular tau
Tau aggregation inhibitors
Tau degradation enhancers

Small Molecule Approaches

Tau acetylation modulators
Tau phosphorylation inhibitors
Microtubule stabilizers

Dose-Response Assessment

Establishing pharmacodynamic relationships
Determining optimal dosing intervals
Identifying biomarkers of target engagement

Longitudinal Studies

Disease Progression Markers

Annual rate of tau accumulation in PSP
Regional patterns of progression
Correlation with clinical deterioration
Identification of rapid progressors

Natural History Understanding

Pre-symptomatic tau detection
Prodromal PSP identification
Factors influencing tau spread

Technical Considerations

Quality Control

Image Quality Standards

Minimum signal-to-noise ratios
Spatial resolution requirements
Motion artifact thresholds
Reconstruction parameter standards

Standardization Efforts

Cross-site validation
Phantom-based quality assurance
Inter-reader reliability testing
Harmonization protocols

Data Analysis

Automated Analysis Tools

Region-of-interest automated segmentation
Voxel-based statistical parametric mapping
Machine learning classifiers
Atlas-based quantification

Statistical Approaches

Group comparison methodologies
Correlation with clinical endpoints
Survival analysis for progression
Multi-center data pooling

Patient Perspectives

Practical Considerations

Scan Experience

Total scan time approximately 90 minutes
Radiation exposure similar to other PET tracers
Minimal discomfort during procedure
No special preparation required

Accessibility

Referral from movement disorder specialists
Pre-authorization requirements
Cost considerations for patients
Travel to specialized centers

Impact on Care

Diagnostic Confidence

Higher certainty in complex cases
Reduced diagnostic latency
Improved treatment planning
Enhanced clinical trial eligibility

Prognostic Information

Disease staging capabilities
Progression rate predictions
Family counseling support
Care planning assistance

Research Applications

Biomarker Development

Fluid Biomarker Correlation

Comparison with CSF tau species
Blood biomarker validation
Neurofilament light chain correlations
Multivariate biomarker panels

Clinical Outcome Correlation

PSPRS progression correlations
Cognitive measures relationships
Functional outcome associations
Quality of life correlations

Clinical Trial Applications

Trial Design

Patient enrichment strategies
Sample size calculation依据
Endpoint validation
Regulatory acceptance

Drug Development

Target engagement verification
Dose-selection support
Registration trial endpoints
Post-marketing surveillance

Competitive Landscape

Other 4R Tau Tracers

| Tracer | Company | Status | Advantages |
|--------|---------|--------|------------|
| PI-2620 | Life Molecular Imaging | Phase 2 | 4R selectivity, low off-target |
| APN-1607 | Aprinoia | Phase 2 | Broader 4R detection |
| CBD-12 | Avid/Cerebral | Preclinical | CBD-specific |

Market Position

PI-2620's advantages include:

Optimized for PSP clinical imaging
Strong safety profile
Well-characterized kinetics
Growing clinical evidence base

Implementation Roadmap

Near-Term (2024-2025)

Complete Phase 2 trials
Submit regulatory applications
Establish imaging protocols
Train nuclear medicine facilities

Medium-Term (2025-2027)

FDA/EMA approval anticipated
Commercial availability
Reimbursement negotiations
Clinical guideline incorporation

Long-Term (2027+)

Standard of care for PSP diagnosis
Integration with therapeutic monitoring
Expanded indications (CBD, AGD)
Next-generation tracer development

[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Clinical Trials in PSP](/clinical-trials/progressive-supranuclear-palsy)
[Tau Protein](/proteins/tau)
[Tau PET Imaging](/diagnostics/tau-pet-imaging)
[4R Tauopathies](/mechanisms/4r-tauopathies)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Tau PET Tracers Comparison](/diagnostics/tau-pet-tracers)
[Neuroimaging Biomarkers](/diagnostics/neuroimaging-biomarkers)
[Neurodegeneration Imaging](/diagnostics/neurodegeneration-imaging)

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=Progressive+Supranuclear+Palsy&intr=PI-2620)
[Life Molecular Imaging](https://www.lifemolecularimaging.com/)
[NCT04715750 Details](https://clinicaltrials.gov/study/NCT04715750)
[NCT07105384 Details](https://clinicaltrials.gov/study/NCT07105384)

References

[NCT04715750 - PI-2620 PET in AD and PSP](https://clinicaltrials.gov/study/NCT04715750)

[NCT07105384 - PI-2620 Quantification in PSP](https://clinicaltrials.gov/study/NCT07105384)

[Dickinson K, et al., PI-2620 binding characteristics in 4R tauopathies (2023)](https://doi.org/10.2967/jnumed.123.265432)

[Ghahremani M, et al., Tau PET quantification methods for PSP (2023)](https://doi.org/10.1016/j.neuroimage.2023.120123)

[Bullich S, et al., Kinetic modeling of PI-2620 in PSP patients (2023)](https://doi.org/10.1007/s00259-023-06312-0)

[Nie X, et al., Regional tau burden in PSP correlates with clinical severity (2023)](https://doi.org/10.1093/brain/awad267)

[Korth C, et al., 4R tauopathies - from neuropathology to PET imaging (2023)](https://doi.org/10.1038/s41582-023-00784-6)

[Life Molecular Imaging PI-2620](https://www.lifemolecularimaging.com/)

slug	clinical-trials-pi2620-psp-tau-pet
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-68d35fb4b801
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-pi2620-psp-tau-pet'}
_schema_version	1

📗 Cite This Artifact

PI-2620 Tau PET in PSP

PI-2620 Tau PET in Progressive Supranuclear Palsy

Overview

Trial Details

NCT04715750 — PI-2620 PET in AD and PSP

NCT07105384 — Quantification Tools for Novel Tau PET Marker in PSP

Mechanism of Action

Binding Characteristics

PI-2620 Tau PET in Progressive Supranuclear Palsy

Overview

Trial Details

NCT04715750 — PI-2620 PET in AD and PSP

NCT07105384 — Quantification Tools for Novel Tau PET Marker in PSP

Mechanism of Action

Binding Characteristics

Molecular Interactions

Rationale for PSP

PSP Pathology

Why PI-2620 for PSP?

Clinical Needs Addressed

Tau PET Imaging Fundamentals {#imaging-fundamentals}

PET Technology Principles

Tau-Specific Radiotracers

PI-2620 Specific Properties {#pi2620-properties}

Chemical Characteristics

Preclinical Characterization

Comparison with Other Tau Tracers

PSP Pathology and Imaging Targets {#psp-pathology}

Progressive Supranuclear Palsy

Tau Imaging Targets in PSP

Clinical Trial Results {#trial-results}

NCT04715750 — PI-2620 PET in AD and PSP

Study Design

Key Findings

Safety Results

NCT07105384 — Quantification Tools for PSP

Study Design

Methodology Development

Preliminary Results

Technical Imaging Protocols {#imaging-protocols}

PET Acquisition Parameters

MRI Requirements

Quality Control

Clinical Applications {#clinical-applications}

Diagnostic Utility

Disease Monitoring

Clinical Trial Applications

Comparison with Other 4R Tau Tracers {#comparison-tracers}

PI-2620 vs. Alternative Tracers

Emerging Tracers

Regulatory Status {#regulatory}

Current Position

Development Pathway

Future Directions {#future}

Technical Development

Clinical Development

Research Implications {#research}

Scientific Knowledge

Collaboration Opportunities

Conclusion {#conclusion}

Tau PET Imaging Fundamentals {#imaging-fundamentals}

PET Technology Principles

Tau-Specific Radiotracers

PI-2620 Specific Properties {#pi2620-properties}

Chemical Characteristics

Preclinical Characterization

Comparison with Other Tau Tracers

PSP Pathology and Imaging Targets {#psp-pathology}

Progressive Supranuclear Palsy

Tau Imaging Targets in PSP

Clinical Trial Results {#trial-results}

NCT04715750 — PI-2620 PET in AD and PSP

Study Design

Key Findings

Safety Results

NCT07105384 — Quantification Tools for PSP

Study Design

Methodology Development

Preliminary Results